JP2008515775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515775A5 JP2008515775A5 JP2007525855A JP2007525855A JP2008515775A5 JP 2008515775 A5 JP2008515775 A5 JP 2008515775A5 JP 2007525855 A JP2007525855 A JP 2007525855A JP 2007525855 A JP2007525855 A JP 2007525855A JP 2008515775 A5 JP2008515775 A5 JP 2008515775A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- years
- stable
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 | |
| US60/601,311 | 2004-08-13 | ||
| PCT/US2005/028861 WO2006020935A2 (en) | 2004-08-13 | 2005-08-12 | Stabilizing formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515775A JP2008515775A (ja) | 2008-05-15 |
| JP2008515775A5 true JP2008515775A5 (cg-RX-API-DMAC7.html) | 2011-11-10 |
| JP4948407B2 JP4948407B2 (ja) | 2012-06-06 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525855A Expired - Fee Related JP4948407B2 (ja) | 2004-08-13 | 2005-08-12 | 安定化処方 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1784219B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4948407B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070092197A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101022831A (cg-RX-API-DMAC7.html) |
| AR (1) | AR051009A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005272603A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0514340A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2575870A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR8904A (cg-RX-API-DMAC7.html) |
| EC (1) | ECSP077246A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2637854T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL181265A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007001599A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20070930L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007109062A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200621282A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006020935A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| MX2008013535A (es) * | 2006-04-21 | 2008-10-29 | Amgen Inc | Agentes amortiguadores para formulaciones biofarmaceuticas. |
| EA018301B1 (ru) * | 2006-04-21 | 2013-07-30 | Новартис Аг | Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| CA2681752A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human 1l-12 antibodies |
| TW200938221A (en) * | 2007-11-30 | 2009-09-16 | Abbott Lab | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| CN104490767A (zh) * | 2009-05-04 | 2015-04-08 | 艾伯维生物技术有限公司 | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 |
| EP2805731B1 (en) | 2009-09-03 | 2018-10-31 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EA026226B1 (ru) * | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| US9675675B2 (en) | 2011-11-30 | 2017-06-13 | 3M Innovative Properties Company | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| PL2830658T3 (pl) * | 2012-03-26 | 2019-02-28 | Sanofi | Stabilne formulacje środków wiążących lgG4 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| WO2014099636A1 (en) * | 2012-12-18 | 2014-06-26 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-tnf alpha antibody |
| BR112016010051A2 (pt) | 2013-11-04 | 2017-12-05 | Pfizer | ?conjugados de anticorpo-fármaco anti-efna4? |
| FI3122426T3 (fi) | 2014-03-28 | 2023-03-31 | Univ Duke | Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| US20160018406A1 (en) * | 2014-07-21 | 2016-01-21 | Unchained Labs Inc. | Determination of Protein Aggregation from the Concentration Dependence of Delta G |
| RU2747228C2 (ru) | 2015-04-29 | 2021-04-29 | Радиус Фармасьютикалз, Инк. | Способы лечения рака |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| CA3254461A1 (en) | 2016-08-18 | 2025-07-03 | Regeneron Pharmaceuticals, Inc. | Assay for Determining Potential to Self-Association of a Protein Using Concentration-Dependent Self-Interaction Nanoparticle Spectroscopy |
| CA3040899A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| LT3565542T (lt) | 2017-01-05 | 2024-07-10 | Radius Pharmaceuticals, Inc. | Polimorfinės rad1901-2hcl formos |
| JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形形態 |
| KR20210127961A (ko) | 2019-02-12 | 2021-10-25 | 래디어스 파마슈티컬스, 인코포레이티드 | 방법 및 화합물 |
| EP4142792A4 (en) * | 2020-05-01 | 2024-11-27 | Kashiv Biosciences, LLC | An improved process of purification of protein |
| CA3207852A1 (en) * | 2021-01-14 | 2022-07-21 | Hanall Biopharma Co., Ltd. | A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3176517D1 (en) | 1980-04-24 | 1987-12-17 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) * | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| WO1998055607A2 (en) | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| WO2001047554A1 (fr) | 1999-12-28 | 2001-07-05 | Chugai Seiyaku Kabushiki Kaisha | Compositions d'anticorps stables et preparations pour injection |
| JP5485489B2 (ja) * | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| EP1324776B2 (en) * | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| WO2003057163A2 (en) * | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
| SG165158A1 (en) | 2002-05-02 | 2010-10-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| AU2003251592A1 (en) * | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CN1867587A (zh) | 2003-08-14 | 2006-11-22 | 惠氏公司 | 抗Lewis Y抗独特型抗体及其用途 |
| TW200616662A (en) * | 2004-09-10 | 2006-06-01 | Wyeth Corp | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es not_active Expired - Lifetime
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja not_active Expired - Fee Related
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en not_active Ceased
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en not_active Expired - Lifetime
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Withdrawn
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515775A5 (cg-RX-API-DMAC7.html) | ||
| RU2007109062A (ru) | Стабилизирующие препараты | |
| Arakawa et al. | Biotechnology applications of amino acids in protein purification and formulations | |
| ES2338218T3 (es) | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. | |
| S Rajan et al. | Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases | |
| JP2010513522A5 (cg-RX-API-DMAC7.html) | ||
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| WO2007147001A3 (en) | Lyophilized formulations of anti-egfr antibodies | |
| JP6253161B2 (ja) | 乾燥された生物学的材料を安定化するための方法及び組成物 | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| US20150018396A1 (en) | Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist | |
| WO2008116103A3 (en) | Stable antibody formulations | |
| IL242372B2 (en) | Anti-4-IL/anti-IL-13 bi-specific antibody preparations | |
| JP2009527251A5 (cg-RX-API-DMAC7.html) | ||
| AR069860A1 (es) | Metodo para purificar un anticuerpo cd20 | |
| JP2013531679A5 (cg-RX-API-DMAC7.html) | ||
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| JP2007534698A5 (cg-RX-API-DMAC7.html) | ||
| JP2016520075A5 (cg-RX-API-DMAC7.html) | ||
| RU2009120200A (ru) | Препараты с высокими концентрациями белка, содержащие маннитол | |
| NZ579395A (en) | Influenza vaccine with improved presevation and stability properties comprising a hydrophobic amino acid, arginine and an acid addition salt | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| Hasan et al. | Osmolytes in vaccine production, flocculation and storage: a critical review | |
| JP2019532267A5 (cg-RX-API-DMAC7.html) |